Security key
90466Y103
UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY)
CUSIP: 90466Y103
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 18,578,488
- Total 13F shares
- 18,997,259
- Share change
- -1,730,215
- Total reported value
- $9,519,281
- Price per share
- $0.50
- Number of holders
- 23
- Value change
- -$954,361
- Number of buys
- 11
- Number of sells
- 9
Report period
Q2 2024
Institutions
23
Top holders
10
UNCY full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Unicycive Therapeutics, Inc. SEC filings
Unicycive Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 90466Y103
Recent filing periods:
Top shareholders of UNCY - UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BVF INC/IL |
13F
|
Company |
19%
|
3,611,601
|
$4,984,009 | — | 31 Mar 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
19%
|
3,470,688
|
$4,789,549 | — | 31 Mar 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
19%
|
3,470,152
|
$4,788,810 | — | 31 Mar 2024 | |
| Logos Global Management LP |
13F
|
Company |
19%
|
3,469,927
|
$3,010,856 | — | 31 Mar 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
18%
|
3,335,586
|
$8,644,198 | — | 31 Mar 2024 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
10%
|
1,879,646
|
$2,593,911 | — | 31 Mar 2024 | |
| Monashee Investment Management LLC |
13F
|
Company |
5.4%
|
1,000,000
|
$1,380,000 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.8%
|
339,860
|
$469,007 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
253,193
|
$349,406 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.5%
|
93,339
|
$128,808 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.5%
|
92,860
|
$128,000 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.37%
|
69,395
|
$95,765 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.19%
|
35,036
|
$48,350 | — | 31 Mar 2024 | |
| Virtu Financial LLC |
13F
|
Company |
0.14%
|
26,082
|
$36,000 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.13%
|
23,998
|
$33,117 | — | 31 Mar 2024 | |
| Ground Swell Capital, LLC |
13F
|
Company |
0.1%
|
19,118
|
$26,383 | — | 31 Mar 2024 | |
| CAPTRUST FINANCIAL ADVISORS |
13F
|
Company |
0.1%
|
18,800
|
$25,944 | — | 31 Mar 2024 | |
| TANDEM CAPITAL MANAGEMENT CORP /ADV |
13F
|
Company |
0.08%
|
15,500
|
$21,390 | — | 31 Mar 2024 | |
| Integrated Wealth Concepts LLC |
13F
|
Company |
0.05%
|
10,000
|
$13,800 | — | 31 Mar 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.04%
|
7,678
|
$10,596 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
4,387
|
$6,054 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
196
|
$270 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
47
|
$65 | — | 31 Mar 2024 | |
| John L. Ryan |
3/4/5
|
Director |
—
class O/S missing
|
123,775
|
— | — | 05 Sep 2023 | |
| Brigitte Schiller |
3/4/5
|
Director |
—
class O/S missing
|
41,738
|
— | — | 15 Jul 2022 |
Institutional Holders of UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY) as of Q2 2024
As of 30 Jun 2024,
UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY) was held by
23 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,997,259 shares.
The largest 10 holders included
Vivo Capital, LLC, Logos Global Management LP, Nantahala Capital Management, LLC, RA CAPITAL MANAGEMENT, L.P., BVF INC/IL, Rosalind Advisors, Inc., VANGUARD GROUP INC, Monashee Investment Management LLC, GEODE CAPITAL MANAGEMENT, LLC, and GOLDMAN SACHS GROUP INC.
This page lists
23
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
21
Q2 2024 holders
23
Holder diff
2
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.